Literature DB >> 2753064

Pharmacokinetics of nitrendipine in terminal renal failure.

L van Bortel1, R Böhm, J Mooy, P Schiffers, K H Rahn.   

Abstract

The pharmacokinetics and plasma protein binding of nitrendipine in patients with terminal renal failure have been compared with those in subjects with normal renal function. Kinetic parameters were calculated after a single 40 mg oral dose, an i.v. injection of 3 mg and after a 15 mg i.v. infusion of nitrendipine. Steady-state plasma levels were determined after 5 days of oral treatment with 20 mg b.d. Pharmacokinetic parameters and steady-state plasma levels in patients with renal failure did not differ from those in subjects with normal renal function. Nitrendipine was as highly bound to plasma proteins in patients with renal failure, as in subjects with normal renal function. The plasma protein did not differ between the two. The dosage of nitrendipine need not be modified for kinetic reasons in patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753064     DOI: 10.1007/bf00558071

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Inter- and intra-subject variability of nitrendipine and the effects of food.

Authors:  J Lobo; D B Jack; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.

Authors:  K D Rämsch; K H Graefe; D Scherling; J Sommer; R Ziegler
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754

3.  Effects of nitrendipine in patients with chronic renal failure.

Authors:  A Dal Canton; C Esposito; M Sabbatini; M Altomonte; G Romano; P Veniero; F Uccello; V E Andreucci
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754

Review 4.  Drug therapy in renal failure.

Authors:  M M Reidenberg; D E Drayer
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

5.  Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers.

Authors:  J Kann; G J Krol; K D Raemsch; D E Burkholder; M J Levitt
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

6.  Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.

Authors:  G R Aronoff
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

7.  Nitrendipine kinetics in normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

8.  Pharmacokinetic and pharmacodynamic parameters in patients treated with nitrendipine.

Authors:  L Hansson; L Andrén; L Orö; T Ryman
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

  8 in total
  9 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

6.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

7.  Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure.

Authors:  H Kierdorf; A Müller; P M Blanke; J Gellert; B Heintz; K D Rämsch; M Wargenau; J Kindler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.